Inhibitors of Tau Oligomer Self Association
Differentiation: Compound screening is performed with full length tau without mutations using conditions promoting oligomer formation, without the use of aggregation enhancers such as heparin that facilitate fibril formation, and without intercalating dyes. This approach best recapitulates tau oligomer formation associated with neurodegeneration and dementias including progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) and Alzheimer’s disease (AD).
Oligomerix’s lead compound is highly differentiated from competitors based on its ability to block tau self-association early in the tau cascade preventing downstream damage. Competitor programs are mostly targeting downstream blockade.
